Dr. Rakesh Koul, MD
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $326.24 | 16 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $204.07 | 10 | $0 (2020) |
| AbbVie Inc. | $64.61 | 3 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $22.29 | 1 | $0 (2022) |
| Novo Nordisk Inc | $21.76 | 1 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $13.51 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $22.29 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($22.29) |
| 2021 | $64.61 | 3 | AbbVie Inc. ($64.61) |
| 2020 | $84.15 | 4 | Allergan, Inc. ($62.39) |
| 2019 | $88.86 | 4 | Allergan Inc. ($88.86) |
| 2018 | $35.19 | 2 | Allergan Inc. ($35.19) |
| 2017 | $31.14 | 2 | Allergan Inc. ($17.63) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Cardio-renal | ||||||
| 11/11/2021 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/07/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/03/2021 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/17/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Diabetes | ||||||
| 08/19/2020 | Allergan, Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/12/2020 | Allergan, Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/16/2020 | Allergan, Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/16/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/16/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/10/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/31/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/27/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/18/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/24/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 561 | 607 | $140,118 | $37,792 |
| 2022 | 7 | 239 | 258 | $52,717 | $17,860 |
| 2021 | 5 | 236 | 240 | $51,428 | $21,569 |
| 2020 | 9 | 296 | 313 | $62,200 | $19,614 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 235 | 249 | $72,653 | $20,623 | 28.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 89 | 89 | $39,145 | $8,633 | 22.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 89 | 91 | $9,100 | $3,150 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 24 | $10,248 | $2,630 | 25.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 19 | $3,382 | $1,016 | 30.0% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 27 | 54 | $2,580 | $875.88 | 33.9% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 44 | 46 | $1,610 | $745.20 | 46.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 35 | 35 | $1,400 | $119.35 | 8.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 80 | $22,304 | $7,791 | 34.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 31 | 31 | $12,687 | $3,804 | 30.0% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 77 | 81 | $8,100 | $2,821 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 14 | $5,470 | $1,822 | 33.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 17 | 18 | $2,709 | $1,223 | 45.1% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 11 | 22 | $1,060 | $357.50 | 33.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 12 | 12 | $387.00 | $41.13 | 10.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 36 | $11,342 | $5,272 | 46.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 49 | $10,539 | $4,982 | 47.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 32 | 32 | $10,315 | $4,140 | 40.1% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 103 | 105 | $10,500 | $3,710 | 35.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $8,732 | $3,464 | 39.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 28 | 28 | $13,472 | $4,425 | 32.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 43 | $13,459 | $3,761 | 27.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 55 | 55 | $11,803 | $3,743 | 31.7% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 33 | 33 | $7,280 | $2,973 | 40.8% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 25 | 25 | $8,035 | $2,456 | 30.6% |
About Dr. Rakesh Koul, MD
Dr. Rakesh Koul, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1124161799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Koul, MD has received a total of $326.24 in payments from pharmaceutical and medical device companies, with $22.29 received in 2022. These payments were reported across 16 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($326.24).
As a Medicare-enrolled provider, Koul has provided services to 1,332 Medicare beneficiaries, totaling 1,418 services with total Medicare billing of $96,836. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Family Medicine
- Location New Hyde Park, NY
- Active Since 02/14/2007
- Last Updated 02/12/2024
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124161799
Products in Payments
- TEFLARO (Drug) $212.59
- AVYCAZ (Drug) $56.09
- Kerendia (Drug) $22.29
- Ozempic (Drug) $21.76
- XARELTO (Drug) $13.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in New Hyde Park
Dr. Jeffrey Silpe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $47,248
Haisam Ismail, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $38,425
Whitney Bowe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $36,934
Stephen Lu
Student in an Organized Health Care Education/Training Program — Payments: $15,950
Dr. Jeffrey Goldstein, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $10,227
Michael Mazer
Student in an Organized Health Care Education/Training Program — Payments: $10,042